Answers are grounded in this paper and cite their sources.
Purpose: To investigate whether glucagon-like peptide-1 receptor agonists are protective against retinal vascular occlusions. Methods: Using a large aggregated, de-identified electronic health records data platform in the United States, patients with type 2 diabetes ages ≥18 years prescribed glucagon-like peptide-1 receptor agonists or non–glucagon-like peptide-1 receptor agonists (controls) and having ophthalmology follow-up of at least 1, 3, or 5 years were included. The glucagon-like peptide-1 receptor agonist and control cohorts were propensity score matched (1:1) on demographics and risk factors, and outcomes were compared at 1, 3, and 5 years. Hazard ratios (HRs) with 95% CIs were reported, with significance defined as P < .05. Results: After matching, each cohort comprised 53 413 patients after 1 year, 25 738 patients after 3 years, and 14 695 patients after 5 years. Significantly reduced risk of all vascular occlusions was observed in the glucagon-like peptide-1 receptor agonist cohort at 1 year (HR, 0.66, 95% CI, 0.54–0.80), 3 years (HR, 0.71, 95% CI, 0.59–0.86), and 5 years (HR, 0.79, 95% CI, 0.64–0.97). Retinal vein occlusion risk was significantly reduced in the glucagon-like peptide-1 receptor agonist cohort up to 3 years (HR, 0.75, 95% CI, 0.60–0.94), but not after 5 years (HR, 0.83, 95% CI, 0.64–1.08). While there was no reduction in retinal artery occlusion risk at 1 year (HR, 0.69, 95% CI, 0.48–1.00), there were significant reductions at later time points. Conclusions: Results suggest that glucagon-like peptide-1 receptor agonists may reduce the risk of retinal vascular occlusions. Additional prospective trials and analysis of long-term outcomes are needed to further investigate this association.
No takes yet. Share an insight, caveat, or question.
Abbass et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: